Punicalagin Ameliorates Lupus Nephritis via Inhibition of PAR2

Punicalagin Ameliorates Lupus Nephritis via Inhibition of PAR2

Lupus nephritis (LN) is the most frequent phenotype in patients with systemic lupus erythematosus (SLE) and has a high rate of progression to end-stage renal disease, in spite of intensive treatment and maintenance therapies. Recent evidence suggests that protease-activated receptor-2 (PAR2) is a th...

Full description

Bibliographic Details
Main Authors: Yohan Seo, Chin Hee Mun, So-Hyeon Park, Dongkyu Jeon, Su Jeong Kim, Taejun Yoon, Eunhee Ko, Sungwoo Jo, Yong-Beom Park, Wan Namkung, Sang-Won Lee
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:International Journal of Molecular Sciences
Subjects:
punicalagin
PAR2
podocyte
systemic lupus erythematosus
lupus nephritis
NZB/W F1 mice
Online Access:https://www.mdpi.com/1422-0067/21/14/4975

Internet

https://www.mdpi.com/1422-0067/21/14/4975

Similar Items